Daiichi Sankyo Seeks FDA Approval Of WelChol With Zetia
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is seeking to update labeling for the cholesterol medication WelChol (colesevelam) to include its use in combination with Schering-Plough/Merck's Zetia (ezetimibe). The Japanese firm's U.S. subsidiary announced the sNDA submission March 28